Eli Lilly Leads R&D Rankings, Relay Shares Up 9%
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Relay Therapeutics reported promising Phase‑2 data for its drug zovegalisib in rare diseases that cause abnormal vasculature development, sending its shares up 9% in premarket trading.
- Eli Lilly topped IDEA Pharma’s R&D performance analysis, ranking first in both innovation (new‑drug revenue) and invention (pipeline size and R&D spend) categories for the first time.
- IDEA Pharma evaluates drugmakers annually on innovation and invention, using revenue from new drugs and the number of drugs in development plus R&D investment as metrics.
Why it matters: Investors in Relay Therapeutics reap an immediate 9% gain, and Lilly’s dual‑ranking boost its reputation, likely attracting capital and partnership deals that can accelerate pipeline funding and market share.
